Abstract
Millions of plastic surgeries are performed worldwide every year with the objective of correcting lipodystrophies stemming from lesions, tumor resections, birth defects, and AIDS-associated antiretroviral therapy. Besides that, a large number of clinical research have assessed the outcome of procedures that rely on combinations of dermal fillers and autologous cells. However, little is known about the safety of these combinations and the localization of the injected cells. The aim of this study was to test the toxicity of a solution containing 1% hyaluronic acid (HA) and adipose-derived stromal cells (ASCs) from the human adipose tissue and to assess the localization of the injected cells, with and without HA, labeled with technetium-99m. Rats received subcutaneous and intraperitoneal injections of a solution containing 1% HA/adipose-derived stromal cells isolated from the human fat tissue. The animals were then observed for up to forty-two days. The solution tested in this study did not result in systemic, biochemical, or anatomic alterations that could represent toxicity symptoms. The association of HA and ASCs labeled with technetium-99m remained at the site of the injection within a period of twenty-four hours, as demonstrated by a whole-body imaging software fusion of SPECT and CT. In conclusion, our study shows that the subcutaneous and intraperitoneal injection of HA associated with adipose-derived stromal cells (ASCs) is safe. The association of HA and ASCs did not induce local or systemic toxicity. Thus, the administration of volume equal to or less than 0.2 mL of the agent filler (1 × 106 ASC+HA 1%) should be considered for subsequent studies and may be an alternative to dermal fillers due to the expected lasting effects.
Highlights
Lipodystrophy syndromes include a heterogeneous group of rare disorders clinically characterized by partial or total absence of subcutaneous adipose tissue and fat deposits in nonadipose tissues such as the liver, muscle, kidney, and pancreas
Several papers have shown the potential benefits of human adipose-derived stem/stromal cells (ASCs) in preclinical and clinical trials; peer-reviewed data on adipose-derived stromal cells (ASCs) have been still limited in the field of aesthetic medicine [14]
Hyaluronic acid, currently the filling product used in aesthetic medicine, presents significant limitations on dermal fillers, including immune reaction and longevity, and some groups have suggested that the ideal dermal filler has not yet been produced [15]
Summary
Lipodystrophy syndromes include a heterogeneous group of rare disorders clinically characterized by partial or total absence of subcutaneous adipose tissue and fat deposits in nonadipose tissues such as the liver, muscle, kidney, and pancreas. Stem Cells International mal fillers [9]. Several papers have shown the potential benefits of human adipose-derived stem/stromal cells (ASCs) in preclinical and clinical trials; peer-reviewed data on ASCs have been still limited in the field of aesthetic medicine [14]. Hyaluronic acid, currently the filling product used in aesthetic medicine, presents significant limitations on dermal fillers, including immune reaction and longevity, and some groups have suggested that the ideal dermal filler has not yet been produced [15]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
